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Abstract
Objectives: To test the antimicrobial sensitivity of two periodontal pathogens to a panel of five orally administra-
ble antibiotics in periodontal disease. 
Study design: A total of 69 isolates of Aggregatibacter actinomycetemcomitans and Porphyromonas gingivalis 
were processed using culture and biochemical tests. Selected colonies of A. actinomycetemcomitans and P. gin-
givalis were used to evaluate the antibacterial activity of clindamycin, metronidazole, amoxicillin, moxifloxacin 
and amoxicillin/clavulanic acid. 
Results: Susceptibility testing revealed a sensitivity of 100% of A. actinomycetemcomitans and P. gingivalis to 
moxifloxacin and amoxicillin/clavulanic acid but moderate susceptibilities were found for the rest of antibiotics 
agents evaluated.
Conclusions: The widespread use of antibiotics is reflected in the level of resistance of A. actinomycetemcomitans and 
P. gingivalis in patients with periodontal infections. This suggests that antibiotic susceptibility testing is necessary to 
determine efficacy of antimicrobial agents. Clinical studies with antibiotics should take these differences into account.
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Introduction
Periodontitis, a chronic inflammatory disease, begins 
with a microbial infection, followed by a host-mediat-
ed destruction of soft tissue caused by hyperactivated 
or primed leukocytes and the generation of cytokines, 
eicosanoids, and matrix metalloproteinases that cause 
clinically significant connective tissue and bone de-
struction (1). Aggregatibacter actinomycetemcomitans 
and Porphyromonas gingivalis are implicated in the 
pathogenesis of periodontitis (2,3). These bacteria are 
able to produce virulence factors that act locally within 
the sulcus, and result in tissue destruction (2,3). Exam-
ples of virulence factors include proteolytic enzymes 
produced by P. gingivalis and leukotoxins produced by 
A. actinomycetemcomitans (3). P. gingivalis has shown 
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the ability to invade human gingival fibroblasts in cell 
culture while P. gingivalis and A. actinomycetemcomi-
tans have all demonstrated the ability to invade human 
oral epithelial cells in cell culture (4). By the way, it is 
noteworthy that 35% of nosocomial pneumonia has been 
demonstrated to be related to periodontopathogens (5).
Invasiveness and ubiquitous intraoral distribution may 
be the main reasons for the reported observation of rath-
er poor results after conventional, merely mechanical 
treatment of periodontal infections (6). Thus, adjunc-
tive systemic antibiotics have been advocated in order 
to suppress the organism in subgingival plaque (7). The 
adjunctive use of systemically administered antibiotics 
has been shown to provide a better clinical outcome, 
particularly in terms of pocket depth reduction and 
attachment-level gain, than scaling and root planing in 
chronic periodontitis subjects (6,7). Commonly used 
antibiotics include clindamycin, metronidazole and 
amoxicillin (6,8). Besides, positive responses have been 
reported with amoxicillin/clavulanic (6,8) and moxi-
floxacin (7) in the treatment of periodontitis. 
Most of the knowledge available on the microbial com-
position of subgingival plaque is based on studies from 
the United States and Europe (8-10), where therapeutic 
oral care programs are available to significant portions 
of the population. Temporal and geographic changes in 
antibiotic susceptibility among anaerobes have been 
reported in Europe (8,10). Besides, the development of 
resistance and significant variation in the local preva-
lence of resistance are well recognized in aerobic and 
anaerobic bacteria in Latin America (9). Determinations 
of MIC values permit early recognition of emerging re-
sistance. For relevant comparative analysis distributions 
of the minimal inhibitory concentration (MIC) values 
are mandatory as the terms susceptible, intermediate 
and resistant are not universally applicable since break-
points may vary in different countries (11).
To the best of our knowledge, there are no studies that 
determine the resistance of A. actinomycetemcomitans 
and P. gingivalis to a panel of five orally administra-
ble antibiotics in periodontal disease. Thus, the present 
study aimed to test, in vitro, the susceptibility to differ-
ent antibiotics of A. actinomycetemcomitans and P. gin-
givalis isolated from subgingival plaque in periodontal 
infections. 
Study Design
Population studied, clinical evaluation, microbiologi-
cal sampling and microbiological procedures. 
A total of 76 adult patients in good general health and 
with no current medication usage were included in the 
study after giving informed consent. Medical history 
and clinical and radiographic examination were con-
ducted for each patient. One of the authors (CA) carried 
out a complete periodontal examination. The following 
clinical parameters were recorded: probing depth (PD), 
clinical attachment level (CAL), and percentages of sites 
with bleeding on probing (BOP) and plaque. A marked 
probe (UNC-15, Hu-Friedy, Chicago, IL) was used in all 
instances. Periodontal diagnosis was established based 
on the consensus report of the American Academy of 
Periodontology (AAP) (12). 
Subgingival microbial samples were taken from the six 
deepest pockets. After removing supragingival plaque 
with curets and isolating the area with cotton pellets, the 
paper points were inserted into each periodontal pocket 
for 20 seconds. The paper points (Maillefer, Ballaigues, 
Switzerland) were pooled in screw cap vials containing 
Viability Medium Götenborg Anaerobically (VMGA) 
III medium (13). All samples were labeled properly and 
processed within 4 hours after sampling. The samples 
were analyzed using microbial culture techniques for 
the presence of periodontopathic bacteria according to 
Slots (14). Briefly, most samples were processed at room 
temperature (25ºC) and incubated in CO2 and anaero-
bic culture systems. Brucella blood agar medium was 
incubated at 35ºC in an anaerobic jar for 7 days. The 
Trypticicase Soy Serum Bacitracin Vancomycin agar 
(TSBV) medium was incubated in 10% CO2 at 37ºC 
for 4 days. Presumptive identification was performed 
according to the methods described (14), and using a 
commercial identification micromethod system (RapID 
ANA II, Remel, Norcross, GA, USA) for A. actinomyc-
etemcomitans and P. gingivalis. Total viable counts 
(TVC) were defined as the total number of colony-
forming units obtained on non-selective media plates. 
Species found on selective media were enumerated and 
their percentage of TVC was calculated.
Antimicrobial susceptibility testing
The susceptibility/resistance of selected colonies of A. 
actinomycetemcomitans and P. gingivalis from pure 
cultures to five antibiotics were measured. The follow-
ing antimicrobials were tested: clindamycin, metro-
nidazole, amoxicillin, moxifloxacin and amoxicillin/
clavulanic acid (E-test®, AB Biodisk, Solna, Sweden). 
Briefly, viable colonies were homogenized in 0.85% sa-
line, and the turbidity was adjusted to MacFarland 1.0 
standard (3 x 108 CFU/ml). Using a sterile glass rod, 
0.1 ml of the inoculums was spread over Brucella blood 
agar plates (BD, Sparks, MD, USA) and dried for 15 
minutes at room temperature. E-test strips were gen-
tly placed onto the agar surface and incubated under 
anaerobic conditions for 4 days. The elliptic zone of in-
hibition was examined after 96 hours of incubation. The 
reading at the intersection of the bacterial zone of inhi-
bition and the E-strip represented the MIC of the organ-
ism. The MIC breakpoints were interpreted according 
to the Clinical Laboratory Standards Institute guide-
lines (15). In the case of A. actinomycetemcomitans, the 
interpretive criteria for the HACEK group were applied 
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Clinical Parameter Mean SD 
Clinical attachment level (mm±SD) 4.3±1.99 
Probing depth (mm±SD) 3.4±1.48 
% sites with plaque (mm±SD) 56±28
% of sites with bleeding on probing  (mm±SD) 77±21
Table 1. Clinical parameters of the periodontal sites being se-
lected for subgingival plaque sampling. 
 MIC (mg/L)a
Microorganism and antibiotic Range 50% 90% Rb (%) IRc (%) Sd (%)  
 
A.  actinomycetemcomitans 
Clindamycin 
 Metronidazole  
 Amoxicillin 
 Moxifloxacin  
 Amoxicillin/clavulanic acid 
 
 
0.016>256 
1.5>256 
0.064-32 
0.19-0.5 
0.02-0.75 
 
 
 
0.125 
6 
0.25 
0.38 
0.25 
 
 
>256 
>256 
32 
0.5 
0.5 
 
 
 
83.33 
88.88 
77.77 
- 
- 
 
 
5.56 
5.56 
- 
- 
- 
 
 
11.11 
5.56 
22.23 
100 
100 
 
 
P. gingivalis  
 Clindamycin 
 Metronidazole  
 Amoxicillin 
 Moxifloxacin  
 Amoxicillin/clavulanic acid  
 
 
 
0.0816 
0.0816 
0.016>256 
0.006-0.032 
<0.016-0.064 
 
 
 
8 
0.256 
0.125 
0.023 
<0.016 
 
 
 
16 
16 
>256 
0.032 
<0.016 
 
 
 
23.52 
21.56 
25.49 
- 
- 
 
 
7.8 
9.8 
- 
- 
- 
 
 
68.68 
68.64 
74.51 
    100 
    100 
 
Table 2. Minimal inhibitory concentration (MIC, mg/ml) across 18 strains of A. actinomycetemcomitans 
and 51 strains of P. gingivalis. 
a50% and 90% indicate the MIC values at which 50% and 90% of isolates were inhibited respectively. bResistance. 
cIntermediate resistance. dSensitive
for amoxicillin/clavulanic acid, whereas for metronida-
zole those for anaerobes were used. As no interpretive 
criteria exist for clindamycin, the interpretive criteria 
for anaerobes were applied (15).
Statistical Analysis
Descriptive analyses were carried out for clinical and 
microbiological parameters. A statistical program was 
used for all the statistical analyses (SPSS, Statistical 
Package for the Social Sciences, version 15, Chicago, 
IL).
Results
Table 1 depicts the clinical characteristics of study sub-
jects. A total of 45 women (59.2%) and 31 men (40.8%) 
with chronic periodontitis were studied. From the 76 
study patients a total of 69 bacterial colonies could be 
clearly identified. Table 2 shows the in vitro susceptibil-
ity of A. actinomycetemcomitans (n=18) and P. gingi-
valis (n=51) to the five antibiotics tested. Susceptibility 
testing revealed a sensitivity of 100% of A. actinomyc-
etemcomitans and P. gingivalis to moxifloxacin and 
amoxicillin/clavulanic acid but moderate susceptibili-
ties were found for the rest of antibiotics agents evalu-
ated.
Discussion
The overuse, misuse and widespread prophylactic ap-
plication of antimicrobial drugs are some of the factors 
that have led to the emergence of drug resistant micro-
organisms (11,16). Microbial resistance has become a 
worldwide medical, economic and public health prob-
lem although microbial resistance rates are not equally 
distributed around the world (9-11,16).  A. actinomyc-
etemcomitans and P. gingivalis represent two important 
periodontal pathogens. In this study, we investigated the 
susceptibility of P. gingivalis and A. actinomycetemcom-
itans from patients with untreated chronic periodontitis; 
their invasiveness and ubiquitous intraoral distribution 
may be the main reasons for the reported observation of 
poor results after mechanical therapy (6). Additionally, 
bacterial resistance to penicillin has become a problem 
of great clinical significance in Latin America because 
of its widespread use for many years (11,16). 
In our study, P. gingivalis was highly susceptible to 
moxifloxacin and amoxicillin/clavulanic acid (Table 2). 
These findings are in agreement with previous studies 
which have found that P. gingivalis is highly suscepti-
ble to these antibiotics (7,8,17,18). Nevertheless, in our 
study 23.52%, 21.56% and 25.49% of the isolates were 
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non-susceptible to clindamycin, metronidazole and 
amoxicillin respectively. Similar results have been re-
ported by other investigations that detected resistances, 
although lower (19). In this viewpoint, it is important 
to note that P. gingivalis has recently been shown to be 
able of transfer plasmid DNA, chromosomal DNA, or 
both which would supply a functional system to also 
transfer resistance determinants (2).
The present findings support that A. actinomycetem-
comitans was the least vulnerable microorganisms. 
Amongst the drugs tested, moxifloxacin and amoxicil-
lin/clavulanic were active against all A. actinomycetem-
comitans isolates in vitro (Table 2). Previous studies of 
the susceptibility of A. actinomycetemcomitans have 
also shown high susceptibility to these two antibiotics 
(6-8, 17,18).  In this study, clindamycin, metronidazole 
and amoxicillin resistance was found amongst A. actino-
mycetemcomitans isolates. Clindamycin, metronidazole 
and amoxicillin resistance observed in this study agrees 
with the studies of van Winkelhoff et al. (8), Madinier et 
al. (20), and Kulik et al. (17) where 82%, 72% and 33% 
of the A. actinomycetemcomitans isolates were non-
susceptible. Once again resistance values found in our 
study were higher. On the other hand, metronidazole 
in combination with amoxicillin has been shown to be 
successful in the treatment of A. actinomycetemcomi-
tans associated periodontal disease (6).  In contrast, the 
MIC90 value of >256 µg/ml of the Spanish A. actino-
mycetemcomitans may indicate that the clinical value of 
this mixture therapy may not be equal in Spain as it is in 
other European countries (8). Analogous situations may 
possibly arise in Latin America.  
Multidrug-resistance is of great concern in skin and soft 
tissue infections, especially in Latin America with a cal-
culated occurrence rate of  24.7% compared with mark-
edly lower rates in Europe (10.8%) and North America 
(3.2%) (16). Latin America also has the lowest suscep-
tibilities of all regions for the following antimicrobials: 
aztreonam, cefepime, ceftazidime, gentamicin, cip-
rofloxacin, imipenem, polymyxin B, and piperacillin/ 
tazobactam (16). Imipenem susceptibilities were low-
est in Latin America at 65.3% compared with Europe 
(80.7%) and North America (88.7%) (16). Imipenem 
resistance is due in part to the appearance and dissemi-
nation of metallo-β-lactamase enzymes that have been 
described repeatedly in Latin America (16). Moreover, 
an increasing prevalence of penicillin resistant pneu-
mococci has been observed throughout the world, and 
Latin America echoes this trend (11).
The results of the present study have shown that moxi-
floxacin and amoxicillin/clavulanic acid were the most 
active antibiotics against A. actinomycetemcomitans 
and P. gingivalis with all the isolates being susceptible. 
Less effective were clindamycin, metronidazole and 
amoxicillin. Owing to geographical differences as well 
as differences over time, we suggest that the overuse 
and misuse of antibiotics could be influencing the man-
ifestation of more highly resistant strains associated 
with periodontal infections in our population. Ongoing 
longitudinal surveillance studies have been crucial to 
the detection and monitoring of regional antimicrobial 
resistance patterns, and continue to provide important 
insights that may serve to modify local prescribing 
guidelines.
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